[33-OR]
Objectives The objective of this study is to determine if chronic infusion of arginine vasopressin (AVP) during mouse pregnancy recapitulates the human phenotypes of preeclampsia. We hypothesize a causative role of elevated AVP in the pathogenesis of preeclampsia. Methods Wildtype C57Bl/6J females were chronically infused with AVP (24 ng/h, s.c., or saline vehicle) before syngeneic mating. Systolic blood pressure during pregnancy was measured by tail-cuff plethysmography. Dams were placed in metabolic cages to collect 24 h urine samples at gestational day (GD) 17; and then sacrificed for necropsy at GD 18. Results In comparison to saline infused females, AVP infused females exhibited a pregnancy specific, significant increase in systolic blood pressure at GD 16 (110 ± 3 vs 120 ± 3 mmHg, p  Conclusions Chronic AVP infusion throughout pregnancy represents a novel, pregnancy specific, clinically relevant model of human preeclampsia that phenocopies all the cardinal physiologic, vascular, obstetric and immunologic phenotypes of human preeclampsia in mice. Disclosures M. Santillan: holds 2 provisional patents on the use of the vasopressin pathway for the prediction, prevention, and treatment of preeclampsia. D. Santillan: None. S. Scroggins: None. J. Sandgren: None. N. Pearson: None. K. Gibson-Corley: None. J. Grobe: holds 2 provisional patents on the use of the vasopressin pathway for the prediction, prevention, and treatment of preeclampsia.